A New Indication In The 1st Line Treatment Of Advanced NSCLC In Combination With Chemotherapy
Meeting Host
Regeneron & OMedLiveDescription
LIBTAYO® (cemiplimab-rwlc) in combination with platinum-based chemotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic.
LIBTAYO as a single agent is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] >e;50%) as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic.
Featured Speakers
- Dr. Martin Dietrich, MD, PhD - Florida Cancer Specialists & Research Institute
- Dr. Jason Porter - West Cancer Center
- Dr. Chaitali Nangia - Hoag Medical Group
When
Date: Tuesday, January 24, 2023
Times: 12:00pm ET, 3:00pm ET, 6:30pm ET
Where
This is a Virtual Meeting.
Meeting Flyer
Meeting details are available on the meeting flyer below.
